Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCarclo Regulatory News (CAR)

Share Price Information for Carclo (CAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.00
Bid: 13.00
Ask: 13.40
Change: 0.20 (1.54%)
Spread: 0.40 (3.077%)
Open: 12.00
High: 13.00
Low: 12.00
Prev. Close: 13.00
CAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Full Year Trading Statement and COVID-19 Update

4 May 2020 07:00

RNS Number : 7390L
Carclo plc
04 May 2020
 

Carclo plc

("Carclo" or "the Group" or "the Company")

 

Full Year Trading Statement and COVID-19 Update

 

Trading update for the year ended 31 March 2020 ("FY2020")

 

The Board is pleased to announce that trading for the continuing businesses during the second half of FY2020 reflected a continuation of the positive momentum seen in the first half of the year. Consequently, the Board expects to report, subject to audit, underlying results for the continuing businesses for FY2020 in line with its expectations.

 

The Technical Plastics Division performed strongly for the year as a whole, largely driven by increased volume as the business continued to secure a number of new programmes in its core medical market. The Aerospace Division also performed well, driven by increased volumes of spares orders and customers building inventory ahead of the UK's exit from the EU.

 

As previously announced, the Group successfully completed the exit from the loss-making businesses of the LED Division in December 2019.

 

The Group's net debt (including IFRS16 leases and subject to audit) at 31 March 2020 was £25.8m, (30 September 2019: £31.7m).

 

Impact of COVID-19

 

Whilst the initial outbreak of COVID-19 had limited impact on trading in final quarter of FY2020, disruption has been more extensive in the first quarter of the current financial year. During this period, the Group's primary focus has been to ensure the wellbeing of staff and the continued safe operation of its businesses. All applicable government advice has been followed across the different countries in which the Group operates. Pleasingly, it has been possible to keep most sites operational through the lockdown period, enabling the Group to continue to serve its customers many of whom operate in essential industries, particularly the medical diagnostic sector.

 

Given the division's focus on the medical market, overall demand across the Technical Plastics business has remained relatively resilient, with a number of its products being used directly in COVID-19 testing applications. Notwithstanding continued demand, the implementation of governmental guidance on social distancing and some limited shutdowns have impacted efficiency and throughput across the Group, which will inevitably have a negative impact on profitability. 

 

Demand for the Aerospace business has been significantly impacted by the downturn in the aerospace sector.

 

Management has already taken action to mitigate these challenges, including accessing government support programmes where available and a reduction in variable costs where appropriate. The Board has taken a 20% cut in fees and salaries for the first quarter of the new financial year. The Group remains focused on ensuring operational continuity where it can; however, it remains very difficult to predict how the ongoing crisis will affect performance going forward. 

 

Outlook

Given the current levels of uncertainty it is not possible for the Board to provide near-term guidance on expected financial performance. As previously reported, discussions continue with the Group's lending bank and pension trustees in order to agree a long-term financing position for Carclo. Whilst these negotiations remain ongoing, there can be no certainty that a satisfactory and affordable agreement will be reached. The Group will make further announcements as appropriate.

Timing of full year results

 

Mindful of the ongoing uncertainty presented by the COVID-19 situation, and the guidance from the Financial Conduct Authority that public companies should consider delaying preliminary announcements, the Board has decided to delay the publication of the Company's Full Year Results for the year ended 31 March 2020 beyond 30 June 2020, the date on which Carclo had previously expected to announce. The revised publication date will be published in due course.

 

Rights attaching to listed equity shares

In compliance with Listing Rule 9.2.6ER(1), the Company has forwarded to the FCA for publication a copy of its Articles of Association, which is the document that sets out the terms and conditions on which its listed equity shares were issued.

A copy of the Articles of Association have been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 

 

 

About Carclo plcCarclo plc is a public company whose shares are quoted on the Main Market of the London Stock Exchange. The Group is a global provider of value-adding engineered solutions for the medical, optical and aerospace industries.

 

 

Enquiries:

Carclo plc 01924 268040

Matt Durkin-Jones - Chief Financial Officer

 

FTI Consulting 020 3727 1340

Nick Hasell / Susanne Yule

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTKZGGKNFZGGZM
Date   Source Headline
18th Feb 202111:19 amRNSHolding(s) in Company
12th Feb 20217:00 amRNSAppointment of Director and CFO
5th Feb 20217:00 amRNSDirector/PDMR Shareholding
4th Feb 20214:35 pmRNSPrice Monitoring Extension
4th Feb 20214:15 pmRNSDirector/PDMR Shareholding
3rd Feb 20214:41 pmRNSSecond Price Monitoring Extn
3rd Feb 20214:35 pmRNSPrice Monitoring Extension
22nd Jan 20217:00 amRNSDirector Appointment
8th Jan 20217:00 amRNSDirector Appointment
7th Jan 202111:35 amRNSDirector/PDMR Shareholding
5th Jan 20214:40 pmRNSDirector/PDMR Shareholding
23rd Dec 20207:00 amRNSFramework Agreement
15th Dec 202010:07 amRNSAppointment of Interim CFO
27th Nov 20207:01 amRNSBoard Changes
27th Nov 20207:00 amRNSHalf Year Results
26th Nov 20204:41 pmRNSSecond Price Monitoring Extn
26th Nov 20204:35 pmRNSPrice Monitoring Extension
12th Nov 20204:33 pmRNSNotice of Interim Results
10th Nov 20204:41 pmRNSSecond Price Monitoring Extn
10th Nov 20204:36 pmRNSPrice Monitoring Extension
5th Oct 20207:00 amRNSBoard restructure
2nd Oct 20204:41 pmRNSSecond Price Monitoring Extn
2nd Oct 20204:36 pmRNSPrice Monitoring Extension
30th Sep 20207:00 amRNSAppointment of Non-Executive Chairman
29th Sep 202012:18 pmRNSResult of AGM
4th Sep 202011:04 amRNS2020 Annual Report & Accounts & Notice of 2020 AGM
25th Aug 20204:46 pmRNSDirector/PDMR Shareholding
25th Aug 20207:00 amRNSPreliminary Results for the year ended 31 March 20
18th Aug 20207:00 amRNSAppointment of NED and Chairman-elect
17th Aug 20207:00 amRNSUpdate on refinancing and current trading
4th May 20204:41 pmRNSSecond Price Monitoring Extn
4th May 20204:35 pmRNSPrice Monitoring Extension
4th May 20207:00 amRNSFull Year Trading Statement and COVID-19 Update
1st May 20204:24 pmRNSHolding(s) in Company
28th Apr 20204:41 pmRNSSecond Price Monitoring Extn
28th Apr 20204:37 pmRNSPrice Monitoring Extension
27th Apr 20207:00 amRNSAppointment of Chairman
14th Apr 20202:41 pmRNSExternal Auditor Appointment
8th Apr 20202:39 pmRNSHolding(s) in Company
8th Apr 20209:03 amRNSHolding(s) in Company
6th Apr 20201:35 pmRNSHolding(s) in Company
3rd Apr 202011:40 amRNSHolding(s) in Company
30th Mar 20204:40 pmRNSSecond Price Monitoring Extn
30th Mar 20204:36 pmRNSPrice Monitoring Extension
24th Mar 20207:00 amRNSDirectorate Change
20th Mar 20204:45 pmRNSSecond Price Monitoring Extn
20th Mar 20204:37 pmRNSPrice Monitoring Extension
19th Mar 20204:42 pmRNSSecond Price Monitoring Extn
19th Mar 20204:37 pmRNSPrice Monitoring Extension
17th Mar 20207:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.